SVCM
SGMT icon

Saturn V Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Saturn V Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4M Buy
+1,479,918
New +$10.1M 1.64% 16

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Saturn V Capital Management's SGMT Position: Q2 2026 in Review

Saturn V Capital Management opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 1,479,918 shares worth $11.4M. The stake represents 1.64% of the portfolio and ranks #16 among its holdings.

110 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Saturn V Capital Management held 1,479,918 shares of Sagimet Biosciences worth $11.4M as of Q2 2026.
  • Sagimet Biosciences was a new Saturn V Capital Management position in Q2 2026.
  • Sagimet Biosciences made up 1.64% of Saturn V Capital Management's portfolio in Q2 2026, its #16 holding.
  • 110 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.